| Outcome |
Author, Year Study/Trial Name | Comparison (IG vs. CG) | Followup | Subgroup | IG n/N (rate per 1,000 screened) | CG n/N (rate per 1,000 screened) | Effect (95% CI) |
|---|---|---|---|---|---|---|---|
| False-positive recall† |
Pattacini, 2022160 RETomo | DBT/DM vs. DM | Round 1 | Ages 45 to 49 | 179/5,053 (35.4) | 194/5,103 (38.0) | RR: 0.93 (95% CI, 0.76 to 1.10)* |
| Ages 50 to 69 | 231/8,303 (27.8) | 267/8,418 (31.7) | RR: 0.88 (95% CI, 0.74 to 1.00)* | ||||
| Round 2 | Ages 45 to 49 | 154/4,813 (32.0) | 177/4,855 (36.5) | RR: 0.88 (95% CI, 0.71 to 1.09)* | |||
| Ages 50 to 69 | 249/7,920 (31.4) | 253/8,056 (31.4) | RR: 1.00 (95% CI, 0.84 to 1.19)* | ||||
|
Hofvind, 2021143 To-Be | DBT/sDM vs. DM | Round 1 | VDG1 | 65/3,929 (16.5) | 91/3,212 (28.3) | RR: 0.58 (95% CI, 0.43 to 0.80)* | |
| VDG2 | 151/6,216 (24.3) | 231/6,280 (36.8) | RR: 0.66 (95% CI, 0.54 to 0.81)* | ||||
| VDG3 | 106/3,152 (33.6) | 121/3,655 (33.1) | RR: 1.02 (95% CI, 0.79 to 1.31)* | ||||
| VDG4 | 24/962 (24.9) | 38/1,136 (33.5) | RR: 0.75 (95% CI, 0.45 to 1.23)* | ||||
| Round 2 | VDG1 | 55/3,214 (17.1) | 62/2,960 (20.9) | RR: 0.81 (95% CI, 0.57 to 1.17)* | |||
| VDG2 | 132/4,353 (30.3) | 142/4,395 (32.3) | RR: 0.94 (95% CI, 0.74 to 1.19)* | ||||
| VDG3 | 114/2,656 (42.9) | 105/2,736 (38.4) | RR: 1.12 (95% CI, 0.86 to 1.45)* | ||||
| VDG4 | 44/900 (48.9) | 29/934 (31.0) | RR: 1.57 (95% CI, 0.99 to 2.49)* | ||||
| False-positive biopsy‡ |
Hofvind, 2021143 To-Be | DBT/sDM vs. DM | Round 1 | VDG1 | 21/3,929 (5.3) | 30/3,212 (9.3) | RR: 0.57 (95% CI, 0.33 to 1.00)* |
| VDG2 | 59/6,216 (9.5) | 93/6,280 (14.8) | RR: 0.64 (95% CI, 0.46 to 0.89)* | ||||
| VDG3 | 68/3,152 (21.6) | 44/3,655 (12.0) | RR: 1.79 (95% CI, 1.23 to 2.61)* | ||||
| VDG4 | 17/962 (17.7) | 18/1,136 (15.8) | RR: 1.12 (95% CI, 0.58 to 2.15)* | ||||
| Round 2 | VDG1 | 30/3,214 (9.3) | 35/2960 (11.8) | RR: 0.79 (95% CI, 0.49 to 1.28)* | |||
| VDG2 | 53/4,353 (12.2) | 61/4,395 (13.9) | RR: 0.88 (95% CI, 0.61 to 1.26)* | ||||
| VDG3 | 52/2,656 (19.6) | 50/2,736 (18.3) | RR: 1.07 (95% CI, 0.72 to 1.57)* | ||||
| VDG4 | 20/900 (22.2) | 10/934 (10.7) | RR: 2.08 (95% CI, 0.98 to 4.41)* |
Relative risk calculated from Ns.
Recalled for assessment without a finding of invasive cancer or DCIS.
Underwent biopsy without a finding of invasive cancer or DCIS.
Abbreviations: CG=control group; CI=confidence interval; DBT=digital breast tomosynthesis; DCIS=ductal carcinoma in situ; DM=digital mammography; IG=intervention group; RETomo=Reggio Emilia Tomosynthesis Trial; RR=relative risk; sDM=synthetic 2-view mammography; To-Be=Tomosynthesis Trial in Bergen; OVVV=Oslo-Vestfold-Vestre Viken; VDG=Volpara Density Grade
From: Chapter 3, Results
NCBI Bookshelf. A service of the National Library of Medicine, National Institutes of Health.